Drugs /

actinium ac 225 lintuzumab

Back to Drugs List

Overview

NCI Definition [1]:
A radioimmunoconjugate consisting of the humanized monoclonal antibody lintuzumab conjugated to the alpha-emitting radioisotope actinium Ac 225 with potential antineoplastic activity. The monoclonal antibody moiety of actinium Ac 225 lintuzumab specifically binds to the cell surface antigen CD33 antigen, delivering a cytotoxic dose of alpha radiation to cells expressing CD33. CD33 is a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on myeloid leukemia cells.

Clinical Trials

View Clinical Trials for actinium ac 225 lintuzumab

Actinium ac 225 lintuzumab has been investigated in 5 clinical trials, of which 4 are open and 1 is closed. Of the trials investigating actinium ac 225 lintuzumab, 3 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open).

CD33 Expression, PML-RARA Fusion, and t(15;17)(q22;q12) are the most frequent biomarker inclusion criteria for actinium ac 225 lintuzumab clinical trials.

Acute myeloid leukemia, multiple myeloma, and secondary acute myeloid leukemia are the most common diseases being investigated in actinium ac 225 lintuzumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Actinium Ac 225 Lintuzumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Actinium Ac 225 Lintuzumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating actinium ac 225 lintuzumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
225ac-hum195, lintuzumab actinium ac-225, actinium-225-labeled humanized anti-cd33 monoclonal antibody hum195
Drug Target(s) [2]:
CD33
NCIT ID [1]:
C82414

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.